Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGFBPL1 (A*02) CAR-T
- Development stage
- Preclinical
- Lead developer
- MyriO Tx
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IGFBPL1 (A*02) CAR-T is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by Myrio Therapeutics for the treatment of neuroblastoma and other pediatric cancers. The therapy utilizes CAR-T cells engineered to recognize a specific peptide derived from Insulin-like growth factor-binding protein-like 1 (IGFBPL1) when presented by the Human Leukocyte Antigen (HLA) allele A*02. This approach allows the T cells to target intracellular or membrane-associated proteins that are processed and presented as MHC-peptide complexes, expanding the targetable proteome beyond surface antigens. Upon recognition of the IGFBPL1-HLA-A*02 complex, the CAR-T cells mediate targeted cytotoxic killing of the tumor cells.
- Other names
- IGFBPL1 CAR-TIGFBPL-1 CAR-TIGFBPL 1 CAR-TIGFBPL1 (A*02)
02
Targets
IGFBPL1/HLA-A*02:01 (Insulin-like growth factor-binding protein-like 1-derived peptide presented by HLA-A*02:01)
Beyond the preview
Go deeper on IGFBPL1 (A*02) CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGFBPL1 (A*02) CAR-T.